financetom
Business
financetom
/
Business
/
Labcorp Holdings Q3 Adjusted Earnings, Revenue Increase; Narrows 2024 Adjusted Earnings Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Labcorp Holdings Q3 Adjusted Earnings, Revenue Increase; Narrows 2024 Adjusted Earnings Guidance
Nov 2, 2024 5:31 AM

07:24 AM EDT, 10/24/2024 (MT Newswires) -- Labcorp Holdings ( LH ) reported Q3 adjusted earnings Thursday of $3.50 per diluted share, up from $3.38 a year earlier.

Analysts polled by Capital IQ expected $3.49.

Revenue for the quarter ended Sept. 30 was $3.28 billion, up from $3.06 billion a year earlier.

Analysts surveyed by Capital IQ expected $3.26 billion.

Labcorp ( LH ) said it now expects fiscal 2024 adjusted EPS of $14.30 to $14.70, compared with its prior outlook of $14.30 to $14.90. Analysts surveyed by Capital IQ expect $14.56.

Price: 222.50, Change: +2.60, Percent Change: +1.18

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Sep 11, 2024
05:10 PM EDT, 09/10/2024 (MT Newswires) -- Samir Desai, Executive Vice President, Chief Digital & Technology Officer, on September 06, 2024, sold 19,041 shares in Abercrombie & Fitch ( ANF ) for $2,501,264. Following the Form 4 filing with the SEC, Desai has control over a total of 27,985 shares of the company, with 27,985 shares held directly. SEC Filing:...
BridgeBio to stop development of therapy for genetic disorder
BridgeBio to stop development of therapy for genetic disorder
Sep 11, 2024
Sept 10 (Reuters) - BridgeBio Pharma ( BBIO ) said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland. The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment. (Reporting by Puyaan Singh; Editing by Shinjini Ganguli)...
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Sep 11, 2024
05:02 PM EDT, 09/10/2024 (MT Newswires) -- Westaim ( WEDXF ) after trade Tuesday said it sold all its remaining 1.91-million shares in Skyward Specialty Insurance Group. The investment-holding company said proceeds, less commissions, were approximately US$79 million. Westaim's ( WEDXF ) remaining investments include significant interests in Arena and the Arena FINCOs. The company's shares closed down $0.04 to...
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sep 11, 2024
05:00 PM EDT, 09/10/2024 (MT Newswires) -- Ric Smith, Chief Product & Technology Officer, on September 06, 2024, sold 51,052 shares in Sentinelone ( S ) for $1,140,682. Following the Form 4 filing with the SEC, Smith has control over a total of 585,647 shares of the company, with 585,647 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1583708/000158370824000078/xslF345X05/wk-form4_1726001520.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved